Join the Graft-versus-host disease group to help and get support from people like you.
Graft-versus-host disease News
Related terms: GVHD
Implant Can Warn Weeks Early That Transplanted Organ Will Be Rejected
FRIDAY, Sept. 8, 2023 – Receiving an organ transplant can be a nerve-wracking, if lifesaving, affair, said Dr. Joaquin Brieva, a kidney transplant recipient. “Within two days of my transplant, my k...
In Primate Study, Antibody Treatment Prevents Organ Rejection After Transplant
THURSDAY, Aug. 31, 2023 – A new study in non-human primates shows potential for using a manmade monoclonal antibody to help prevent organ rejection after a transplant. The antibody was successful in...
U.S. FDA Approves Imbruvica (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the t...
U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)
PRINCETON, N.J.--(BUSINESS WIRE) December 15, 2021 – Bristol Myers Squibb (NYSE:BMY) today announced that Orencia (abatacept) was approved by the U.S. Food and Drug Administration (FDA) for the p...
Incyte Announces FDA Approval of Jakafi (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Jakafi is approved for treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older Today’s approval marks the fourth F...
FDA Approves Rezurock (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
NEW YORK, NY / ACCESSWIRE / July 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezurock™ (belumosudil) 200 mg once daily ...
FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
WILMINGTON, Del.--(BUSINESS WIRE)--May 24, 2019-- Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of...
FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease
August 2, 2017 – The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after...
Ask a question
To post your own question to this support group, sign in or create an account.